keyword
MENU ▼
Read by QxMD icon Read
search

Sunitinib

keyword
https://www.readbyqxmd.com/read/29164297/dose-and-schedule-modification-are-required-for-long-term-continuation-of-sunitinib-in-japanese-patients-with-advanced-pancreatic-neuroendocrine-tumors
#1
Lingaku Lee, Tetsuhide Ito, Hisato Igarashi, Masami Miki, Nao Fujimori, Ken Kawabe, Robert T Jensen, Yoshihiro Ogawa
PURPOSE: This study aimed to clarify the efficacy and safety of sunitinib in Japanese patients with pancreatic neuroendocrine tumors (PNET), especially by focusing on dose and schedule modification. METHODS: Sixteen patients with advanced PNET treated with sunitinib were reviewed retrospectively. Efficacy was evaluated by progression-free survival (PFS) and objective tumor response. Toxicity profile was assessed regularly. Correlation between relative dose intensity (RDI) and treatment period was also evaluated...
November 21, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29161241/determination-of-an-optimal-response-cut-off-able-to-predict-progression-free-survival-in-patients-with-well-differentiated-advanced-pancreatic-neuroendocrine-tumours-treated-with-sunitinib-an-alternative-to-the-current-recist-defined-response
#2
Angela Lamarca, Jorge Barriuso, Matthew Kulke, Ivan Borbath, Heinz-Josef Lenz, Jean Luc Raoul, Neal J Meropol, Catherine Lombard-Bohas, James Posey, Sandrine Faivre, Eric Raymond, Juan W Valle
BACKGROUND: Sunitinib prolongs progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumours (pNET). Response Evaluation Criteria in Solid Tumors (RECIST)-defined partial responses (PR; classically defined as ⩾30% size decrease from baseline) are infrequent. METHODS: Individual data of pNET patients from the phase II [NCT00056693] and pivotal phase III [NCT00428597] trials of sunitinib were analysed in this investigator-initiated, post hoc study...
November 21, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29158141/patient-reported-tolerance-in-treatments-approved-in-neuroendocrine-tumors-a-national-survey-from-the-french-group-of-endocrine-tumors
#3
Arnaud Plante, Eric Baudin, Christine Do Cao, Olivia Hentic, Olivier Dubreuil, Eric Terrebonne, Victoire Granger, Denis Smith, Catherine Lombard-Bohas, Thomas Walter
BACKGROUND: Patients with advanced neuroendocrine tumors (NETs) benefit from an increasing number of treatments. The patient's preference could help physicians to choose among these options. Our patient-reported survey aims to compare the perceived tolerance of NETs treatments. METHODS: Patients treated by at least three different therapeutic options have evaluated their perceived tolerance from one (very good) to five (very poor) for each single treatment. Referent physician confirmed the type and ranking over time of each treatment...
November 17, 2017: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/29156837/meta-analysis-of-efficacy-and-adverse-events-of-erlotinib-based-targeted-therapies-for-advanced-metastatic-non-small-cell-lung-cancer
#4
Fei Li, Shu-Hua Zhang, Li-Min Pang
A network meta-analysis evaluating efficacy and adverse events of eight erlotinib-based therapies (erlotinib+placebo, erlotinib+tivantinib, erlotinib+celecoxib, erlotinib+onartuzumab, erlotinib+sunitinib, erlotinib+entinostat, erlotinib+sorafenib, and erlotinib+bevacizumab) for advanced/metastatic non-small-cell lung cancer (NSCLC) was performed. PubMed and Cochrane Library were reviewed, and ten randomized controlled trials were identified in which patients receiving at least one erlotinib-based therapy. Efficacy outcomes, including progression-free survival (PFS), overall survival (OS), overall response rate (ORR), disease control rate (DCR), and adverse outcomes were evaluated...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156834/oncolytic-reovirus-inhibits-angiogenesis-through-induction-of-cxcl10-ip-10-and-abrogation-of-hif-activity-in-soft-tissue-sarcomas
#5
Jennifer S Carew, Claudia M Espitia, Weiguo Zhao, Monica M Mita, Alain C Mita, Steffan T Nawrocki
The tumor-selective viral replication capacity and pro-apoptotic effects of oncolytic reovirus have been reported to be dependent on the presence of an activated RAS pathway in several solid tumor types. However, the mechanisms of selective anticancer efficacy of the reovirus-based formulation for cancer therapy (Reolysin, pelareorep) have not been rigorously studied in soft tissue sarcomas (STS). Here we report that Reolysin triggered a striking induction of the anti-angiogenic chemokine interferon-γ-inducible protein 10 (IP-10)/CXCL10 (CXC chemokine ligand 10) in both wild type and RAS mutant STS cells...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29152075/a-novel-multikinase-inhibitor-r8-exhibits-potent-inhibition-on-cancer-cells-through-both-apoptosis-and-autophagic-cell-death
#6
Yuqiong Xie, Chunchun Li, Yali Huang, Zhenyu Jia, Jiang Cao
Chemotherapy is an important treatment for cancer patients, especially for those with unresectable lesions. Targeted therapy of cancer by specific inhibition of aberrant tyrosine kinase activities in cancer cells with chemically synthesized tyrosine kinase inhibitors (TKIs), shows better responses while less side effects than traditional chemotherapeutic drugs. It is common that cancer cells often exhibit deregulation of several tyrosine kinases simultaneously, multikinase TKIs (MKIs) therefore have greater advantages over single-target TKIs...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29146887/targeted-therapy-of-gastroenteropancreatic-neuroendocrine-tumours-preclinical-strategies-and-future-targets
#7
Elke Tatjana Aristizabal Prada, Christoph J Auernhammer
Molecular targeted therapy of advanced neuroendocrine tumours (NETs) of the gastroenteropancreatic (GEP) system currently encompasses approved therapy with the mTOR-inhibitor everolimus and the multi-tyrosinkinase inhibitor sunitinib. However clinical efficacy of these treatment strategies is limited by low objective response rates and limited progression free survival due to tumor resistance. Further novel strategies for molecular targeted therapy of NETs of the GEP-system are needed. This paper reviews preclinical research models and signaling pathways in NETs of the GEP-system...
November 16, 2017: Endocrine Connections
https://www.readbyqxmd.com/read/29146618/management-of-adverse-events-associated-with-cabozantinib-therapy-in-renal-cell-carcinoma
#8
REVIEW
Manuela Schmidinger, Romano Danesi
Cabozantinib was recently approved for the treatment of advanced renal cell carcinoma (RCC) after treatment with vascular endothelial growth factor (VEGF)-targeted therapy. Cabozantinib is a multikinase inhibitor targeting VEGF receptor (VEGFR) 2, mesenchymal-epithelial transition receptor, and "anexelekto" receptor tyrosine kinase. A 60-mg daily dose led to improved overall survival and progression-free survival (PFS) versus everolimus in advanced RCC patients as a second- or later-line treatment in the METEOR trial...
November 16, 2017: Oncologist
https://www.readbyqxmd.com/read/29145240/gastrointestinal-stromal-tumor-gist-with-liver-metastases-an-18-year-experience-from-the-gist-cooperation-group-in-north-china
#9
Yi-Nan Shi, Yong Li, Li-Ping Wang, Zhen-Hua Wang, Xiao-Bo Liang, Han Liang, Li Zhang, Bin Li, Li-Qiao Fan, Qun Zhao, Zhi-Xue Ma, Xue-Feng Zhao, Zhi-Dong Zhang, Yu Liu, Bi-Bo Tan, Dong Wang, Li-Li Wang, Ying-Jie Hao, Nan Jia
Approximately 40% to 50% of gastrointestinal stromal tumor (GIST) patients will have recurrence or metastases after resection of the primary lesion, and the most common affected sites will be liver and peritoneum. Imatinib has been considered as the first-line therapy of metastatic GIST. Surgery for metastases is proposed when possible. Furthermore, there are controversies concerning hepatic resection and systemic tyrosin kinase inhibitors (TKIs). The therapeutic conditions and long-term outcome of GIST patients with liver metastases in northern China remain unknown...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29143892/update-in-the-therapy-of-advanced-neuroendocrine-tumors
#10
REVIEW
Inbal Uri, Shani Avniel-Polak, David J Gross, Simona Grozinsky-Glasberg
Neuroendocrine tumors (NETs) are rare neoplasms, with an estimated annual incidence of ~ 6.9/100,000. NETs arise throughout the body from cells of the diffuse endocrine system. More than half originate from endocrine cells of the gastrointestinal tract and the pancreas, thus being referred to as gastroenteropancreatic NETs (GEP-NETs). The only treatment that offers a cure is surgery; however, most patients are diagnosed with metastatic disease, and curative surgery is usually not an option. These patients can be offered long-term systemic treatment, for both symptomatic relief and tumor growth suppression...
November 16, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29141865/development-and-plasticity-of-meningeal-lymphatic-vessels
#11
Salli Antila, Sinem Karaman, Harri Nurmi, Mikko Airavaara, Merja H Voutilainen, Thomas Mathivet, Dmitri Chilov, Zhilin Li, Tapani Koppinen, Jun-Hee Park, Shentong Fang, Aleksanteri Aspelund, Mart Saarma, Anne Eichmann, Jean-Léon Thomas, Kari Alitalo
The recent discovery of meningeal lymphatic vessels (LVs) has raised interest in their possible involvement in neuropathological processes, yet little is known about their development or maintenance. We show here that meningeal LVs develop postnatally, appearing first around the foramina in the basal parts of the skull and spinal canal, sprouting along the blood vessels and cranial and spinal nerves to various parts of the meninges surrounding the central nervous system (CNS). VEGF-C, expressed mainly in vascular smooth muscle cells, and VEGFR3 in lymphatic endothelial cells were essential for their development, whereas VEGF-D deletion had no effect...
November 15, 2017: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/29140528/evaluation-of-renal-function-change-during-first-line-tyrosine-kinase-inhibitor-therapy-for-metastatic-renal-cell-carcinoma
#12
Hiroki Ishihara, Tsunenori Kondo, Hironori Fukuda, Kazuhiko Yoshida, Kenji Omae, Toshio Takagi, Junpei Iizuka, Hirohito Kobayashi, Kazunari Tanabe
Background: The change in renal function induced by first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma remains unclear. Methods: One hundred and thirty-four patients were evaluated. Sunitinib (SU) and sorafenib (SO) were administered to 91 (67.9%) and 43 (32.1%) patients, respectively. The change in estimated glomerular filtration rate (ΔeGFR) was calculated as [(eGFR at each time point - pre-treatment eGFR)/pre-treatment eGFR] × 100...
November 13, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29134564/seom-clinical-guideline-for-treatment-of-kidney-cancer-2017
#13
E Gallardo, M J Méndez-Vidal, J L Pérez-Gracia, J M Sepúlveda-Sánchez, M Campayo, I Chirivella-González, X García-Del-Muro, A González-Del-Alba, E Grande, C Suárez
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma...
November 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29128510/enzymes-involved-in-tumor-driven-angiogenesis-a-valuable-target-for-anticancer-therapy
#14
REVIEW
Biagio Ricciuti, Jennifer Foglietta, Vanessa Bianconi, Amirhossein Sahebkar, Matteo Pirro
Angiogenesis plays a pivotal role in cancer progression and is required for tissue invasion and metastasis. Starting with Folkman's initial observations in 1971, basic research continued to shed new molecular insight into this multifaceted process, leading to the development of several anti-angiogenic drugs. To date, anti-vascular endothelial growth factor monoclonal antibodies, such as bevacizumab and ramucirumab, and receptor tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, regorafenib and axitinib) have had a profound impact on the way we treat patients with advanced cancer, providing in some cases unprecedented clinical benefit...
November 8, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29121860/pneumatosis-cystoides-intestinalis-associated-with-sunitinib-and-a-literature-review
#15
Yong Suk Lee, Jae Joon Han, Si-Young Kim, Chi Hoon Maeng
BACKGROUND: Pneumatosis cystoides intestinalis (PCI) is a rare self-limiting condition characterized by air-filled cysts within intestinal walls. Diagnosis should be prudent because it can mimic pneumoperitoneum leading to unnecessary treatment such as surgical exploration. Although various drugs including anti-neoplastic agents have been suggested as etiologies, cases related to sunitinib are sparse. Because of the rarity of this unusual side effect by sunitinib, we report the case report...
November 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29118527/unusual-pattern-of-whitening-of-eyebrows-following-sunitinib-therapy-a-case-report-with-brief-review-of-literature
#16
Chaturbhuj R Agrawal, Vineet Talwar, Venkata Pradeep Babu, Parveen Jain, Pankaj Goyal
Sunitinib is a vascular endothelial growth factor receptor inhibitor which has shown high activity in metastatic renal cell carcinoma (mRCC) patients and is now widely used for the same. It is generally well tolerated, but sometimes, it exhibits a distinct pattern of novel side effects that require monitoring and management. Important known side effect of sunitinib includes fatigue, diarrhea, anorexia, skin toxicity, and hypertension which need special mention. Considering its effectiveness in first-line setting in mRCC and paucity of other good options, utmost efforts are made to continue it with identification of side effects which may require only slight dose modification or no dose alteration...
October 2017: International Journal of Trichology
https://www.readbyqxmd.com/read/29113767/renal-functional-outcome-of-partial-nephrectomy-for-complex-r-e-n-a-l-score-tumors-with-or-without-neoadjuvant-sunitinib-a-multicenter-analysis
#17
Michelle L McDonald, Brian R Lane, Juan Jimenez, Hak J Lee, Kendrick Yim, Ahmet Bindayi, Zachary A Hamilton, Charles A Field, Aaron S Bloch, Sumi Dey, Sabrina Noyes, Rana McKay, Frederick Millard, Brian I Rini, Steven C Campbell, Ithaar H Derweesh
BACKGROUND: Sunitinib might optimize the feasibility of partial nephrectomy (PN) for complex renal tumors with imperative indications. We compared the renal functional outcomes of patients with complex renal masses who had undergone sunitinib before PN with those of patients who had not required neoadjuvant sunitinib before PN. PATIENTS AND METHODS: We performed a multicenter retrospective analysis of patients with renal cell carcinoma who had undergone PN for a complex renal mass (R...
September 25, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29111348/nrpa-308-a-new-neuropilin-1-antagonist-exerts-in%C3%A2-vitro-anti-angiogenic-and-anti-proliferative-effects-and-in%C3%A2-vivo-anti-cancer%C3%A2-effects-in-a-mouse-xenograft-model
#18
Wang-Qing Liu, Yves Lepelletier, Matthieu Montès, Lucia Borriello, Rafika Jarray, Renaud Grépin, Bertrand Leforban, Ali Loukaci, Rachid Benhida, Olivier Hermine, Sylvie Dufour, Gilles Pagès, Christiane Garbay, Françoise Raynaud, Reda Hadj-Slimane, Luc Demange
Neuropilin-1 (NRP-1) is an extra-cellular receptor for the main Vascular Endothelial Growth Factor over-expressed in tumour tissues, VEGF-A165. Consequently, NRP-1 is involved in angiogenesis and in tumour growth, and its over-expression is related to a clinical poor prognosis. NRP-1 appears as a major target in oncology, which remains poorly exploited. Herein, we report a new series of 18 small-sized fully organic VEGF-A165/NRP-1 antagonists (NRPas). These compounds share an original scaffold, including two linkers (sulphonamide and amide) and three aromatic cores...
October 28, 2017: Cancer Letters
https://www.readbyqxmd.com/read/29110655/treatment-of-gastrointestinal-stromal-tumours-in-paediatric-and-young-adult-patients-with-sunitinib-a-multicentre-case-series
#19
Piotr Rutkowski, Heather Magnan, Alexander J Chou, Charlotte Benson
BACKGROUND: Gastrointestinal stromal tumours (GIST) are rarely encountered mesenchymal tumours of the gastrointestinal tract (1.5 people per 100,000/year) that are even more rarely seen in paediatric patients (1-2% of all cases). The standard treatment for advanced adult GIST is imatinib with sunitinib as a second-line option. Although the efficacy and tolerability of sunitinib in adults with GIST has been established, little is known of the profile of sunitinib in paediatric/young adult patients with GIST given the rarity of this disease...
November 6, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29103264/suppressors-for-human-epidermal-growth-factor-receptor-2-4-her2-4-a-new-family-of-anti-toxoplasmic-agents-in-arpe-19-cells
#20
Yeong Hoon Kim, Lokraj Bhatt, Hye-Jin Ahn, Zhaoshou Yang, Won-Kyu Lee, Ho-Woo Nam
The effects of tyrosine kinase inhibitors (TKIs) were evaluated on growth inhibition of intracellular Toxoplasma gondii in host ARPE-19 cells. The number of tachyzoites per parasitophorous vacuolar membrane (PVM) was counted after treatment with TKIs. T. gondii protein expression was assessed by western blot. Immunofluorescence assay was performed using Programmed Cell Death 4 (PDCD4) and T. gondii GRA3 antibodies. The TKIs were divided into 3 groups; non-epidermal growth factor receptor (non-EGFR), anti-human EGFR 2 (anti-HER2), and anti-HER2/4 TKIs, respectively...
October 2017: Korean Journal of Parasitology
keyword
keyword
21148
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"